Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Watson gets US and Canadian rights to PregLem's Esmya

Executive Summary

Two months after being acquired by Gedeon Richter Ltd., PregLem SA (women's reproductive products) has granted generics company Watson Laboratories Inc. (a division of Watson Pharmaceuticals Inc.) exclusive US and Canadian rights to Esmya (ulipristal) for uterine fibroids.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies